Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > ORGANIZATION
ORGANIZATION
- Hight Time to Hold Fundamental Debate on Drug Price Revisions: FPMAJ Director General
March 24, 2023
- Japan Umbrella Trade Organ to Beef Up Functions for Lobbying Activity
March 24, 2023
- Over 20% of All Generics under Restricted Shipments: FPMAJ
March 14, 2023
- PhRMA Unveils Proposal for FY2024 Reform, Says This Year Is “Turning Point” to Improve Access
March 10, 2023
- Labor Unions Prod MHLW to Renew Efforts to Improve Compliance with Drug Distribution Guidelines
March 3, 2023
- OB/GYN Group Urges MHLW to Facilitate Access to Oral Abortion Drug
February 24, 2023
- Policy Veterans’ Group Floats Proposal to Prevent Unprofitability to Stabilize Drug Supply
February 21, 2023
- JPMA Chief Calls for Prompt Price Cuts for LLPs, Generic Industry Consolidation
February 17, 2023
- Japan Citizen’s Group Objects Pfizer’s Partnership with Tokyo Govt
February 1, 2023
- PhRMA Poised to Issue 2024 Reform Proposal in Next Few Months: New Japan Chief
January 25, 2023
- Kenporen Director Calls on Pharma Industry, MHLW to Share More Data toward FY2024 Reform
January 20, 2023
- JPMA Now Finalizing Policy Proposal 2023, Due Out “before Cherry Blossoms”
January 20, 2023
- Japan Pharma Lobbies Look Set to Shift to Okada/Ueno Leadership towards FY2024 Reform
January 17, 2023
- ALS Patient Group Petitions for Early Approval of Relyvrio in Japan
January 12, 2023
- FPMAJ Chief Poised to Push Rethink of Price Revision Rules towards FY2024 Reform
January 11, 2023
- Japan Pharma Leaders Want to Thwart “Drug Loss,” Return of Lag: New Year’s Messages
January 5, 2023
- FPMAJ Calls on Drug Makers to Lift Shipment Controls of 233 APIs/Specifications
December 28, 2022
- Generic Use Rate Hits Record 80.3% in July-September: JGA
December 28, 2022
- Hodanren Questions Special PMP Measure in Off-Year Drug Price Revision
December 27, 2022
- Product Coverage for FY2023 Price Revision “Deeply Regrettable”: FPMAJ
December 22, 2022
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…